Literature DB >> 24719131

Histogram analysis of hepatobiliary phase MR imaging as a quantitative value for liver cirrhosis: preliminary observations.

Jin-Young Choi1, Honsoul Kim1, Mark Sun2, Claude B Sirlin2.   

Abstract

PURPOSE: To investigate whether histogram analysis of the hepatobiliary phase on gadoxetate enhanced-MRI could be used as a quantitative index for determination of liver cirrhosis.
MATERIALS AND METHODS: A total of 63 patients [26 in a normal liver function (NLF) group and 37 in a cirrhotic group] underwent gadoxetate-enhanced MRI, and hepatobiliary phase images were obtained at 20 minutes after contrast injection. The signal intensity of the hepatic parenchyma was measured at four different regions of interest (ROI) of the liver, avoiding vessels and bile ducts. Standard deviation (SD), coefficient of variation (CV), and corrected CV were calculated on the histograms at the ROIs. The distributions of CVs calculated from the ROI histogram were examined and statistical analysis was carried out.
RESULTS: The CV value was 0.041±0.009 (mean CV±SD) in the NLF group, while that of cirrhotic group was 0.071±0.020. There were statistically significant differences in the CVs and corrected CV values between the NLF and cirrhotic groups (p<0.001). The most accurate cut-off value among CVs for distinguishing normal from cirrhotic group was 0.052 (sensitivity 83.8% and specificity 88.5%). There was no statistically significant differences in SD between NLF and cirrhotic groups (p=0.307).
CONCLUSION: The CV of histograms of the hepatobiliary phase on gadoxetate-enhanced MRI may be useful as a quantitative value for determining the presence of liver cirrhosis.

Entities:  

Keywords:  Cirrhosis; gadoxetate disodium; histogram; magnetic resonance imaging

Mesh:

Substances:

Year:  2014        PMID: 24719131      PMCID: PMC3990078          DOI: 10.3349/ymj.2014.55.3.651

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  39 in total

1.  Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation.

Authors:  Takahiro Tsuboyama; Hiromitsu Onishi; Tonsok Kim; Hirofumi Akita; Masatoshi Hori; Mitsuaki Tatsumi; Atsushi Nakamoto; Hiroaki Nagano; Nariaki Matsuura; Kenichi Wakasa; Kaname Tomoda
Journal:  Radiology       Date:  2010-06       Impact factor: 11.105

2.  Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging.

Authors:  Mustafa R Bashir; Elmar M Merkle
Journal:  Eur Radiol       Date:  2010-08-05       Impact factor: 5.315

3.  Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.

Authors:  Haruo Watanabe; Masayuki Kanematsu; Satoshi Goshima; Hiroshi Kondo; Minoru Onozuka; Noriyuki Moriyama; Kyongtae T Bae
Journal:  Radiology       Date:  2011-01-19       Impact factor: 11.105

4.  Assessment of liver viscoelasticity using multifrequency MR elastography.

Authors:  Patrick Asbach; Dieter Klatt; Uwe Hamhaber; Jürgen Braun; Rajan Somasundaram; Bernd Hamm; Ingolf Sack
Journal:  Magn Reson Med       Date:  2008-08       Impact factor: 4.668

Review 5.  MR imaging of liver fibrosis: current state of the art.

Authors:  Silvana C Faria; Karthik Ganesan; Irene Mwangi; Masoud Shiehmorteza; Barbara Viamonte; Sameer Mazhar; Michael Peterson; Yuko Kono; Cynthia Santillan; Giovanna Casola; Claude B Sirlin
Journal:  Radiographics       Date:  2009-10       Impact factor: 5.333

Review 6.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.

Authors:  Nina F Schwenzer; Fabian Springer; Christina Schraml; Norbert Stefan; Jürgen Machann; Fritz Schick
Journal:  J Hepatol       Date:  2009-06-11       Impact factor: 25.083

Review 7.  Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications.

Authors:  Jayant A Talwalkar; Meng Yin; Jeff L Fidler; Schuyler O Sanderson; Patrick S Kamath; Richard L Ehman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index.

Authors:  Laurent Huwart; Christine Sempoux; Najat Salameh; Jacques Jamart; Laurence Annet; Ralph Sinkus; Frank Peeters; Leon C ter Beek; Yves Horsmans; Bernard E Van Beers
Journal:  Radiology       Date:  2007-11       Impact factor: 11.105

Review 9.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

10.  New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI.

Authors:  Natsuko Tsuda; Masahiro Okada; Takamichi Murakami
Journal:  Eur J Radiol       Date:  2008-11-20       Impact factor: 3.528

View more
  4 in total

1.  Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?

Authors:  Kumar Sandrasegaran; Enming Cui; Reem Elkady; Pauley Gasparis; Gitasree Borthakur; Mark Tann; Suthat Liangpunsakul
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

2.  Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression.

Authors:  Christopher R Bradley; Eleanor F Cox; Naaventhan Palaniyappan; Susan T Francis; Indra Neil Guha; Guruprasad P Aithal
Journal:  Eur Radiol Exp       Date:  2022-10-24

3.  Histogram analysis of gadoxetic acid-enhanced MRI for quantitative hepatic fibrosis measurement.

Authors:  Honsoul Kim; Seong Ho Park; Eun Kyung Kim; Myeong-Jin Kim; Young Nyun Park; Hae-Jeong Park; Jin-Young Choi
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

4.  Histogram Analysis of Diffusion Kurtosis Magnetic Resonance Imaging for Diagnosis of Hepatic Fibrosis.

Authors:  Ruo-Fan Sheng; Kai-Pu Jin; Li Yang; He-Qing Wang; Hao Liu; Yuan Ji; Cai-Xia Fu; Meng-Su Zeng
Journal:  Korean J Radiol       Date:  2018-08-06       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.